HMGvsMelanotan II

Human Menopausal Gonadotropin is a purified urinary extract containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, sourced from the urine of postmenopausal women. After menopause, the loss of ovarian negative feedback (estradiol and inhibin) results in dramatically elevated pituitary gonadotropin secretion — FSH and LH levels rise 10-20 fold, providing a natural source of these hormones for pharmaceutical extraction.

The FSH component binds to FSH receptors (FSHR) on Sertoli cells in males and granulosa cells in females. FSHR is a Gs-coupled GPCR that activates cAMP/PKA signaling, driving the expression of genes essential for gametogenesis. In males, FSH-stimulated Sertoli cells produce androgen-binding protein (which concentrates testosterone locally), inhibin B (which provides negative feedback to the pituitary), and multiple growth factors that support spermatogonial proliferation and differentiation through the stages of spermatogenesis. In females, FSH drives follicular development — stimulating granulosa cell proliferation, estradiol synthesis via aromatase induction, and the growth of ovarian follicles from the pre-antral to the pre-ovulatory stage.

The LH component acts on Leydig cells in males (stimulating testosterone production via the LHCGR/cAMP/StAR steroidogenic pathway) and on theca cells in females (stimulating androgen precursor production that granulosa cells convert to estradiol). In females undergoing fertility treatment, the LH component is also critical for final oocyte maturation and ovulation triggering. The combination of both FSH and LH activity in HMG provides more complete gonadal stimulation than either gonadotropin alone — FSH drives the cellular proliferation and maturation processes while LH provides the steroidogenic and final maturation signals. This dual activity is why HMG is sometimes preferred over purified FSH preparations in certain fertility protocols, particularly in hypogonadotropic patients who lack endogenous LH.

Melanotan II is a synthetic cyclic heptapeptide analogue of α-MSH with a fundamentally different receptor profile from the linear Melanotan I. Its cyclic structure (achieved through a lactam bridge between aspartic acid and lysine residues) provides metabolic stability and, critically, non-selective binding to multiple melanocortin receptors (MC1R through MC5R), producing a diverse range of physiological effects.

MC1R activation on melanocytes drives the same eumelanin production pathway as MT-I: cAMP → PKA → CREB → MITF → tyrosinase/TRP-1/TRP-2, resulting in skin darkening independent of UV exposure. However, MT-II's additional activation of MC3R and MC4R in the hypothalamus produces effects that MT-I does not. MC4R is a key regulator of sexual function and energy balance — its activation in the paraventricular nucleus stimulates sexual arousal and erectile function through descending autonomic pathways, while simultaneously suppressing appetite through inhibition of orexigenic NPY/AgRP neurons. This is why MT-II produces the notable combination of tanning, increased libido, and reduced appetite.

MC3R activation contributes to energy homeostasis regulation and may modulate natriuresis (sodium excretion). MC5R activation on exocrine glands may affect sebaceous gland secretion. The non-selective nature of MT-II's receptor activation is both its appeal (multiple desired effects from one compound) and its primary safety concern — the broad melanocortin activation means effects cannot be isolated, and the tanning effect raises concerns about melanocyte stimulation in pre-existing moles and nevi. Unlike MT-I, which received FDA approval for a specific indication, MT-II's non-selective profile and cosmetic use case have prevented regulatory approval, and it is actively discouraged by health authorities in most countries.